Targeting Immunotherapy to the Tumor Microenvironment

J Cell Biochem. 2017 Oct;118(10):3049-3054. doi: 10.1002/jcb.26005. Epub 2017 May 15.

Abstract

Targeting drugs to the tumor microenvironment has long been appreciated as a means of increasing local concentrations and decreasing systemic toxicities. How drug targeting might apply to immune-based therapies is less clear. In this review, we explain the immunology of cancer, with a focus on the principles of in situ vaccination. Certain types of therapies are more amenable to local versus systemic delivery; these include cytokines, adjuvants, radiation, and agents targeting tumor-resident cell populations. Several approaches for targeting the tumor microenvironment are under development. Nanoparticles, peptide or antibody-based delivery, and exploitation of cellular influx are all promising ways to delivery immune modulating compounds to tumors. J. Cell. Biochem. 118: 3049-3054, 2017. © 2017 Wiley Periodicals, Inc.

Keywords: CANCER IMMUNOLOGY; DRUG TARGETING; IMMUNOTHERAPY; TUMOR MICROENVIRONMENT.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use*
  • Drug Delivery Systems / methods*
  • Humans
  • Neoplasms / drug therapy*
  • Neoplasms / metabolism
  • Neoplasms / pathology
  • Tumor Microenvironment / drug effects*

Substances

  • Antineoplastic Agents